1. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study. Issue 2 (16th February 2021) Authors: Hutchings, Martin; Radford, John; Ansell, Stephen M.; Illés, Árpád; Sureda, Anna; Connors, Joseph M.; Sýkorová, Alice; Shibayama, Hirohiko; Abramson, Jeremy S.; Chua, Neil S.; Friedberg, Jonathan W.; Kořen, Jan; LaCasce, Ann Steward; Molina, Lysiane; Engley, Gerald; Fenton, Keenan; Jolin, Hina; L... Journal: Hematological oncology Issue: Volume 39:Issue 2(2021) Page Start: 185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy. Issue 2 (21st November 2016) Authors: Chu, Michael P.; Lieffers, Jessica; Ghosh, Sunita; Belch, Andrew; Chua, Neil S.; Fontaine, Amelie; Sangha, Randeep; Turner, Robert A.; Baracos, Vickie E.; Sawyer, Michael B. Journal: Journal of cachexia, sarcopenia and muscle Issue: Volume 8:Issue 2(2017) Page Start: 298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗